Tsumoto, Kouhei
Takeuchi, Tsutomu http://orcid.org/0000-0003-1111-8218
Funding for this research was provided by:
Taisho Pharmaceutical Company
Saitama Medical University
Article History
Accepted: 13 January 2024
First Online: 8 April 2024
Declarations
:
: Funding support for the original clinical studies of ozoralizumab was provided by Taisho Pharmaceutical Co., Ltd. In addition, Taisho Pharmaceutical Co., Ltd. provided funding for editorial support and publication of the article.
: Kouhei Tsumoto and Tsutomu Takeuchi have received honoraria for lectures and consulting fees from Taisho Pharmaceutical Co. Ltd.
: Not applicable.
: Not applicable.
: Not applicable.
: The data generated and/or analyzed in the cited papers of ozoralizumab used to write this review article was supplied by Taisho Pharmaceutical Co., Ltd. under license and, therefore, cannot be made freely available. Requests for access to these data should be made to the corresponding author.
: Not applicable.
: TT drafted the overall concept and primarily wrote the manuscript regarding the clinical trials. KT mainly prepared the manuscript for the fragment antibody and ozoralizumab (Sects. and ). All authors read and approved the final manuscript.